Condition: Small Cell Lung Cancer (SCLC) · Extensive-stage Small Cell Lung Cancer (ES-SCLC) · Sponsor: Boehringer Ingelheim
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker DLL3. Participants are put into 2 groups randomly, which means by chance. One group receives obrixtamig and standard treatment. The other group receives standard treatment without obrixtamig. All treatments are given as infusions into a vein. Participants are in the study for up to 3 years. During this time, they visit the study site regularly. Participants in the group receiving obrixtamig stay overnight at the study site following the first 2 obrixtamig treatments. At the visits, doctors check the size of the tumour(s). The results are compared between the 2 groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
This description comes directly from the study's public registry record.
Boehringer Ingelheim · 1-800-243-0127 · clintriage.rdg@boehringer-ingelheim.com
Always discuss trial participation with your own doctor first.
| Infirmary Cancer Care | Mobile, Alabama, United States | Not Yet Recruiting |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | Not Yet Recruiting |
| Bioresearch Partner - Hialeah Hospital | Hialeah, Florida, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Norton Cancer Institute, Downtown | Louisville, Kentucky, United States | Not Yet Recruiting |
| Pikeville Medical Center | Pikeville, Kentucky, United States | Not Yet Recruiting |
| Epic Medical Research - Monroe | Monroe, Louisiana, United States | Not Yet Recruiting |
| Ochsner Medical Center | New Orleans, Louisiana, United States | Not Yet Recruiting |
| Epic Medical Research - Shreveport | Shreveport, Louisiana, United States | Not Yet Recruiting |
| University of Maryland School of Medicine | Baltimore, Maryland, United States | Not Yet Recruiting |
| Veterans Affairs Ann Arbor Healthcare System | Ann Arbor, Michigan, United States | Not Yet Recruiting |
| HCA MidAmerica Division, Inc. | Kansas City, Missouri, United States | Recruiting |
+ 230 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07472517